Skip to content
Screener

Eli Lilly LLY Reportable Segment — Marketing, selling, and administrative

Similar metrics at other companies

Neurocrine Biosciences logo
NBIXReportable Segment — Selling, general, and administrative
$318.5M+15.2%
Arcutis Biotherapeutics, Inc. logo
ARQTReportable Segment — Selling, general, and administrative
$82.01M+18.8%
Novavax logo
NVAXReportable Segment — Selling, general, and administrative
$26.67M-38.9%
CSL
CSLReportable Segments — Selling and administrative expenses
$160.43M+6.8%
Lowe's Companies logo
LOWReportable Segment — Selling, General and Administrative Expense
$4.19B+3.6%
Target logo
TGTReportable Segment — Selling, general, and administrative expenses
$5.56B+21.2%

Other financials

Income statement

See full
Revenue$23.0B+47.7%
Gross profit$19.7B+50.3%
Net income$7.1B+25.3%
EPS (diluted)$7.94+26.2%

Balance sheet

See full
Cash & equivalents$9.0B+165%
Total debt$54.9B+37.6%
Total equity$33.9B+85.4%
Total assets$142.28B+41.0%

Cash flow

See full
Operating cash flow$10.7B+246%
CapEx$2.9B+72.8%
Free cash flow$7.8B+458%

Valuation

See full
Market cap$1.06T+58.6%
Enterprise value$1.11T+56.9%
P/E39.8×-8.8×
P/S13.3×+0.8×

Profitability

See full
Gross margin83.4%+0.8pp
Net margin33.5%+7.6pp
FCF margin22.8%+13.7pp

Returns & leverage

See full
Return on equity102.4%+15.7pp
Debt / equity1.6×-0.6×
Current ratio1.4×+0.1×

Where this comes from

Reported directly by Eli Lilly in its filing.

Tagged under the XBRL concept us-gaap:SellingGeneralAndAdministrativeExpense.

The source filing: Eli Lilly’s 10-Q, filed August 5, 2026.

Filed
Aug 5, 2026, 2:40 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0000059478-26-000081
Line itemThree Months Ended June 30, 2026Three Months Ended June 30, 2025Six Months Ended June 30, 2026Six Months Ended June 30, 2025
Cost of sales3,2682,4486,8454,672
Early-stage research and development(1)1,4501,1562,7152,146
Late-stage research and development(1)2,3682,1804,6133,924
Marketing, selling, and administrative3,4302,7536,3645,221
Acquired in-process research and development2,7761543,3601,726
Other segment items(2)2,5871,2074,3842,177
Net income$7,095$5,661$14,491$8,420
Interest expense$345$249$677$493

Item 1. Financial Statements

FAQ

What is Eli Lilly's reportable segment — marketing, selling, and administrative?
Eli Lilly (LLY) reported reportable segment — marketing, selling, and administrative of $3.43B in Q2 2026.
How has Eli Lilly's reportable segment — marketing, selling, and administrative changed year-over-year?
Eli Lilly's reportable segment — marketing, selling, and administrative increased by 24.6% year-over-year, from $2.75B to $3.43B.
What is the long-term trend for Eli Lilly's reportable segment — marketing, selling, and administrative?
Over 3 years (2022 to 2025), Eli Lilly's reportable segment — marketing, selling, and administrative has grown at a 19.9% compound annual growth rate (CAGR), from $6.44B to $11.09B.
What does reportable segment — marketing, selling, and administrative mean?
Captures the operating expenses related to the promotion, distribution, and general management of the segment's business activities. This includes sales force compensation, advertising, and administrative overhead required to support commercial operations. It reflects the investment intensity required to maintain the segment's competitive position.

Ask your AI about Eli Lilly's reportable segment — marketing, selling, and administrative.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude